Key Takeaways

A prospective trial of gastrointestinal cancer patients showed the feasibility of preemptive genetic testing for DPYD/UGT1A1 variants associated with increased chemotherapy toxicity.

Genotype-guided dose reductions resulted in numerically fewer chemotherapy side effects and treatment discontinuations or modifications.

Testing results were available before chemotherapy was initiated for more than half of the patients.

Genetic testing of gastrointestinal cancer patients prior to starting chemotherapy proved feasible in a prospective study and showed a signal for a reduced risk of serious side effects.

Compared with patients who received standard dose chemotherapy, those who had a tailored dose of chemotherapy based on rapid genetic testing for variants in DPYD and UGT

See Full Page